ERBB2 and breast carcinoma: SorLA silencing inhibits 3D spheroid growth induced by heregulin-enriched stroma, and sensitizes metastatic breast cancer cells to the HER2/EGFR dual tyrosine kinase inhibitor neratinib in an in vivo xenograft model of brain tumors.